• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma.

作者信息

Pal Sumanta K, Bergerot Paulo, Dizman Nazli, Bergerot Cristiane, Adashek Jacob, Madison Russell, Chung Jon H, Ali Siraj M, Jones Jeremy O, Salgia Ravi

机构信息

Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.

Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.

出版信息

Eur Urol. 2018 Jul;74(1):124-128. doi: 10.1016/j.eururo.2018.03.032.

DOI:10.1016/j.eururo.2018.03.032
PMID:29685646
Abstract
摘要

相似文献

1
Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma.ALK重排的乳头状肾细胞癌对阿来替尼的反应。
Eur Urol. 2018 Jul;74(1):124-128. doi: 10.1016/j.eururo.2018.03.032.
2
ALK Inhibition With Alectinib for Refractory Metastatic Renal Cell Carcinoma With ALK Rearrangement: A Rare Case Report and Literature Review.阿来替尼治疗伴有 ALK 重排的难治性转移性肾细胞癌：一例罕见病例报告及文献复习。
JCO Precis Oncol. 2024 Jun;8:e2400154. doi: 10.1200/PO.24.00154.
3
A Case of Squamous Cell Carcinoma Harboring an EML4-ALK Rearrangement that Was Unsuccessfully Treated with the ALK Inhibitor Alectinib.一例携带EML4-ALK重排的鳞状细胞癌病例，使用ALK抑制剂阿来替尼治疗失败。
J Thorac Oncol. 2015 Aug;10(8):e74. doi: 10.1097/JTO.0000000000000575.
4
The use of alectinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer.阿来替尼在间变性淋巴瘤激酶阳性非小细胞肺癌一线治疗中的应用。
Future Oncol. 2018 Aug;14(18):1875-1882. doi: 10.2217/fon-2018-0027. Epub 2018 Mar 14.
5
Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.在对阿来替尼耐药的两个存在 ALK 重排的非小细胞肺癌（NSCLC）患者中发现了一种新型的 HIP1-ALK 融合变体和 ALK I1171（I1171N/S）突变。
J Thorac Oncol. 2014 Dec;9(12):1821-5. doi: 10.1097/JTO.0000000000000368.
6
Sequential Use of Anaplastic Lymphoma Kinase Inhibitors in Japanese Patients With ALK-Rearranged Non-Small-Cell Lung Cancer: A Retrospective Analysis.日本间变性淋巴瘤激酶重排非小细胞肺癌患者序贯使用间变性淋巴瘤激酶抑制剂：一项回顾性分析
Clin Lung Cancer. 2017 Jul;18(4):e251-e258. doi: 10.1016/j.cllc.2016.11.015. Epub 2016 Dec 7.
7
ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature.对阿来替尼有反应的ALK重排肺鳞状细胞癌：一例报告并文献复习
BMC Cancer. 2017 Jul 6;17(1):471. doi: 10.1186/s12885-017-3468-1.
8
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.克唑替尼耐药的间变性淋巴瘤激酶（ALK）重排非小细胞肺癌（NSCLC）患者中艾乐替尼针对全身疾病和脑转移的安全性和活性：一项 1/2 期研究剂量探索部分的结果。
Lancet Oncol. 2014 Sep;15(10):1119-28. doi: 10.1016/S1470-2045(14)70362-6. Epub 2014 Aug 18.
9
Protocol Design for the Bench to Bed Trial in Alectinib-Refractory Non-Small-Cell Lung Cancer Patients Harboring the EML4-ALK Fusion Gene (ALRIGHT/OLCSG1405).针对携带EML4-ALK融合基因的阿来替尼难治性非小细胞肺癌患者的从实验室到临床研究的方案设计（ALRIGHT/OLCSG1405）
Clin Lung Cancer. 2016 Nov;17(6):602-605. doi: 10.1016/j.cllc.2016.05.005. Epub 2016 Jun 2.
10
Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer.阿来替尼治疗转移性ALK重排非小细胞肺癌的安全性。
Expert Opin Drug Saf. 2017 Apr;16(4):509-514. doi: 10.1080/14740338.2017.1299706. Epub 2017 Mar 3.

引用本文的文献

1
ALK-positive adult histiocytosis with a TFG-ALKfusion gene.伴有TFG-ALK融合基因的ALK阳性成人组织细胞增多症
Oncologist. 2025 Sep 1;30(9). doi: 10.1093/oncolo/oyaf221.
2
Paediatric renal tumors: An insight into molecular characteristics, histomorphology and syndromic association.小儿肾肿瘤：对分子特征、组织形态学及综合征关联的深入见解
World J Nephrol. 2025 Jun 25;14(2):99380. doi: 10.5527/wjn.v14.i2.99380.
3
Current Evidences and Future Perspectives in the Management of Metastatic Non-Clear Cell Renal Cell Carcinoma.转移性非透明细胞肾细胞癌治疗的当前证据与未来展望
Int J Urol. 2025 Sep;32(9):1118-1128. doi: 10.1111/iju.70144. Epub 2025 Jun 9.
4
Systemic Treatment of Locally Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma.局部晚期或转移性非透明细胞肾细胞癌的全身治疗
Cancers (Basel). 2025 Apr 30;17(9):1527. doi: 10.3390/cancers17091527.
5
Tumour-agnostic kinase inhibitors.肿瘤非特异性激酶抑制剂。
Nat Rev Drug Discov. 2025 Mar 6. doi: 10.1038/s41573-025-01147-y.
6
[Molecularly defined renal cell carcinomas].[分子定义的肾细胞癌]
Pathologie (Heidelb). 2025 Feb;46(1):5-12. doi: 10.1007/s00292-024-01408-4. Epub 2025 Jan 27.
7
Paediatric renal tumours: an update on challenges and recent developments.小儿肾肿瘤：挑战与最新进展综述
Virchows Arch. 2025 Jan;486(1):49-64. doi: 10.1007/s00428-024-04017-x. Epub 2025 Jan 9.
8
If it is a solid tumor target, then it may be a hematologic cancer target: Bridging the great divide.如果它是实体瘤靶点，那么它可能是血液系统癌症靶点：弥合巨大差距。
Med. 2025 Jan 10;6(1):100550. doi: 10.1016/j.medj.2024.11.003. Epub 2024 Dec 16.
9
Complete morphologic response to gilteritinib in ALK-rearranged acute myeloid leukemia.在ALK重排的急性髓系白血病中对吉瑞替尼的完全形态学反应
NPJ Precis Oncol. 2024 Sep 10;8(1):197. doi: 10.1038/s41698-024-00701-y.
10
Anaplastic Lymphoma Kinase (ALK)-Rearranged Renal Cell Carcinoma: A Case Report Highlighting Diagnostic Challenges and Therapeutic Opportunities.间变性淋巴瘤激酶（ALK）重排的肾细胞癌：一例报告，凸显诊断挑战与治疗机遇
Cureus. 2024 Jul 29;16(7):e65621. doi: 10.7759/cureus.65621. eCollection 2024 Jul.